UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender

British journal of dermatology (1951), 2021-02, Vol.184 (2), p.243-258

2021

Volltextzugriff (PDF)

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

British journal of dermatology (1951), 2013-04, Vol.168 (4), p.844-854

2013

Volltextzugriff (PDF)

The global state of psoriasis disease epidemiology: a workshop report

British journal of dermatology (1951), 2017-07, Vol.177 (1), p.e4-e7

2017

Volltextzugriff (PDF)

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

British journal of dermatology (1951), 2020-08, Vol.183 (2), p.294-302

2020

Volltextzugriff (PDF)

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population‐based cohort study

British journal of dermatology (1951), 2017-03, Vol.176 (3), p.650-658

2017

Volltextzugriff (PDF)

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.928-938

2017

Volltextzugriff (PDF)

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)

British journal of dermatology (1951), 2020-05, Vol.182 (5), p.1158-1166

2020

Volltextzugriff (PDF)

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

British journal of dermatology (1951), 2018-03, Vol.178 (3), p.674-681

2018

Volltextzugriff (PDF)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

British journal of dermatology (1951), 2021-06, Vol.184 (6), p.1047-1058

2021

Volltextzugriff (PDF)

Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults

British journal of dermatology (1951), 2020-07, Vol.183 (1), p.128-138

2020

Volltextzugriff (PDF)

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.890-901

2017

Volltextzugriff (PDF)

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study

British journal of dermatology (1951), 2019-05, Vol.180 (5), p.1069-1076

2019

Volltextzugriff (PDF)

Adherence to medication in patients with psoriasis: a systematic literature review

British journal of dermatology (1951), 2013-01, Vol.168 (1), p.20-31

2013

Volltextzugriff (PDF)

Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register

British journal of dermatology (1951), 2015-08, Vol.173 (2), p.510-518

2015

Volltextzugriff (PDF)

Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease

British journal of dermatology (1951), 2021-09, Vol.185 (3), p.646-648

2021

Volltextzugriff (PDF)

The promise and challenges of cell therapy for psoriasis

British journal of dermatology (1951), 2021-11, Vol.185 (5), p.887-898

2021

Volltextzugriff (PDF)

The role of the microbiome in psoriasis: moving from disease description to treatment selection?

British journal of dermatology (1951), 2018-05, Vol.178 (5), p.1020-1027

2018

Volltextzugriff (PDF)

Optimizing the use of biologgers for movement ecology research

The Journal of animal ecology, 2020-01, Vol.89 (1), p.186-206

2020

Volltextzugriff (PDF)

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

British journal of dermatology (1951), 2015-05, Vol.172 (5), p.1395-1406

2015

Volltextzugriff (PDF)

Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

British journal of dermatology (1951), 2021-12, Vol.185 (6), p.1146-1159

2021

Volltextzugriff (PDF)

Risk of hospitalization and death due to infection in people with psoriasis: a population‐based cohort study using the Clinical Practice Research Datalink

British journal of dermatology (1951), 2021-01, Vol.184 (1), p.78-86

2021

Volltextzugriff (PDF)

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study

Journal of the European Academy of Dermatology and Venereology, 2017-01, Vol.31 (1), p.119-126

2017

Volltextzugriff (PDF)

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

British journal of dermatology (1951), 2021-11, Vol.185 (5), p.935-944

2021

Volltextzugriff (PDF)

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

British journal of dermatology (1951), 2018-01, Vol.178 (1), p.132-139

2018

Volltextzugriff (PDF)

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

British journal of dermatology (1951), 2021-12, Vol.185 (6), p.1124-1134

2021

Volltextzugriff (PDF)

1 – 25 von 13.204

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(10.142)
Mit Volltextzugriff
(10.951)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(7.031)
Life Sciences & Biomedicine
(5.261)
Humans
(3.888)
Female
(2.123)
Male
(2.054)
Biological And Medical Sciences
(2.024)
Medical Sciences
(1.469)
Physical Sciences
(1.263)
Adult
(1.246)
Middle Aged
(1.217)
Animals
(1.150)
Aged
(995)
Technology
(761)
Fundamental And Applied Biological Sciences. Psychology
(642)
Dermatology
(573)
Adolescent
(529)
Physics
(528)
Exact Sciences And Technology
(493)
General & Internal Medicine
(420)
Child
(392)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(4.955)
EZB Electronic Journals Library
(4.525)
IngentaConnect Journals
(4.426)
Journals@Ovid Ovid Full Text
(4.073)
Wiley Online Library
(2.271)
Publisher or Other Site
(2.154)
Elsevier ScienceDirect Journals Complete
(1.973)
IngentaConnect Journals
(1.689)
Wiley Online Library
(1.670)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.446)
Oxford Journals
(1.152)
Jstor Complete Legacy
(972)
Springer Nature - Complete Springer Journals
(770)
BMJ_英国医学会期刊
(554)
Ebook Central Perpetual and DDA
(528)
Taylor & Francis Online
(495)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(482)
eBooks on EBSCOhost
(477)
Taylor & Francis Journals
(464)
Taylor & Francis
(459)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

The global state of psoriasis disease epidemiology: a workshop report

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population‐based cohort study

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial

Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study

Adherence to medication in patients with psoriasis: a systematic literature review

Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register

Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease

The promise and challenges of cell therapy for psoriasis

The role of the microbiome in psoriasis: moving from disease description to treatment selection?

Optimizing the use of biologgers for movement ecology research

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

Risk of hospitalization and death due to infection in people with psoriasis: a population‐based cohort study using the Clinical Practice Research Datalink

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

Suchergebnisse filtern